Product Information
ABACAVIR-LAMIVUDINE 600-300 MG is a generic product labeled by Laurus Labs Limited, priced at $1.4542 per EA under NDC 42385096230. Its NADAC has been published 183 times since Dec 28, 2022.
Strength
600; 300 mg/1; mg/1
Manufacturer
Laurus Labs LimitedNDC
42385096230
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
ABACAVIR SULFATE; LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA216332On Market Since
7/25/2022
Pharmacological Classes
Price Statistics
The NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has been published 183 times since Dec 28, 2022, and over the history we have for it it has declined 43.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4542 per EA |
|---|---|
| All-time high | $2.5767 (Feb 15, 2023) |
| All-time low | $1.2091 (Nov 22, 2023) |
| 52-week high | $1.6992 |
| 52-week low | $1.2621 |
| Median price | $1.5666 |
| Average price | $1.6062 |
| Largest weekly change | -39.9% (Nov 22, 2023) |
| Weeks tracked | 183 |
| Tracking since | Dec 28, 2022 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ABACAVIR-LAMIVUDINE 600-300 MG?
The current National Average Drug Acquisition Cost (NADAC) for ABACAVIR-LAMIVUDINE 600-300 MG, manufactured by Laurus Labs Limited, is $1.4542 per EA (NDC 42385096230), effective Jun 24, 2026.
How has the price of ABACAVIR-LAMIVUDINE 600-300 MG changed over time?
Over the history we have for it, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has declined 43.6%. It has been tracked across 183 weekly CMS publications since Dec 28, 2022.
What are the highest and lowest recorded NADAC prices for ABACAVIR-LAMIVUDINE 600-300 MG?
Since Dec 28, 2022, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has ranged from a low of $1.2091 (Nov 22, 2023) to a high of $2.5767 (Feb 15, 2023), with a median of $1.5666 per EA.
Are there cheaper alternatives to ABACAVIR-LAMIVUDINE 600-300 MG?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as ABACAVIR-LAMIVUDINE 600-300 MG, but none are currently priced below it.
Who manufactures ABACAVIR-LAMIVUDINE 600-300 MG?
ABACAVIR-LAMIVUDINE 600-300 MG (NDC 42385096230) is labeled by Laurus Labs Limited, and CMS classifies it as a generic product.
Related Drugs
Same classification